Prediction of success for HIFU treatments of prostate cancer based on acoustic energy density

Russell J. Fedewa, Roy F. Carlson, Ralf Seip, Narendra T. Sanghvi, Michael Koch, Thomas Gardner

Research output: Chapter in Book/Report/Conference proceedingConference contribution

2 Citations (Scopus)

Abstract

A novel method [1] to predict the probability of success of prostate cancer treatments with HIFU immediately after treatment was developed. It is based on an acoustic energy density measure computed by dividing the energy delivered during a HIFU treatment by the prostate gland volume. This method has been implemented in the Sonablate®500 (SB-500) HIFU prostate cancer device (Focus Surgery, Inc., Indianapolis, USA). Its utility was verified by correlating the energy density index to the 180 day post-treatment biopsy results for each subject enrolled in a Phase I clinical trial (N=19) for the primary treatment of organ confined prostate cancer with the SB-500. For each HIFU treatment and at each treatment site the total acoustic power (TAP) and the HIFU "ON" time were recorded. This information, along with the dimensions of the prostate prior to HIFU treatment and an estimated tissue attenuation coefficient were used to compute the energy density measure. Two values for the attenuation coefficient at 4 MHz were used to estimate the energy absorbed by the prostate: infinite attenuation (α=∞) and finite attenuation (α=0.32 Np/cm). The energy density results for subjects with a negative biopsy were found to be significantly higher than the energy density results for subjects with a positive biopsy when using either infinite or finite attenuation estimates (p<0.02 for both). Receiver operator characteristics (ROC) were computed using the post-treatment biopsy as a gold standard. The area under the ROC curve was found to be 0.77 and 0.80 for infinite and finite attenuation value. This developed energy density measure will not replace current HIFU prostate cancer treatment success indicators (i.e. biopsy), but its ability to be computed immediately post-HIFU treatment and its high correlation with clinical success indicators makes it a useful measure of treatment success.

Original languageEnglish
Title of host publicationProceedings - IEEE Ultrasonics Symposium
Pages732-735
Number of pages4
Volume1
DOIs
StatePublished - 2006

Fingerprint

flux density
cancer
acoustics
predictions
attenuation
attenuation coefficients
receivers
prostate gland
operators
estimates
surgery
organs
energy
curves

Keywords

  • HIFU
  • Prostate cancer
  • Ultrasound

ASJC Scopus subject areas

  • Acoustics and Ultrasonics

Cite this

Fedewa, R. J., Carlson, R. F., Seip, R., Sanghvi, N. T., Koch, M., & Gardner, T. (2006). Prediction of success for HIFU treatments of prostate cancer based on acoustic energy density. In Proceedings - IEEE Ultrasonics Symposium (Vol. 1, pp. 732-735). [4152052] https://doi.org/10.1109/ULTSYM.2006.196

Prediction of success for HIFU treatments of prostate cancer based on acoustic energy density. / Fedewa, Russell J.; Carlson, Roy F.; Seip, Ralf; Sanghvi, Narendra T.; Koch, Michael; Gardner, Thomas.

Proceedings - IEEE Ultrasonics Symposium. Vol. 1 2006. p. 732-735 4152052.

Research output: Chapter in Book/Report/Conference proceedingConference contribution

Fedewa, RJ, Carlson, RF, Seip, R, Sanghvi, NT, Koch, M & Gardner, T 2006, Prediction of success for HIFU treatments of prostate cancer based on acoustic energy density. in Proceedings - IEEE Ultrasonics Symposium. vol. 1, 4152052, pp. 732-735. https://doi.org/10.1109/ULTSYM.2006.196
Fedewa RJ, Carlson RF, Seip R, Sanghvi NT, Koch M, Gardner T. Prediction of success for HIFU treatments of prostate cancer based on acoustic energy density. In Proceedings - IEEE Ultrasonics Symposium. Vol. 1. 2006. p. 732-735. 4152052 https://doi.org/10.1109/ULTSYM.2006.196
Fedewa, Russell J. ; Carlson, Roy F. ; Seip, Ralf ; Sanghvi, Narendra T. ; Koch, Michael ; Gardner, Thomas. / Prediction of success for HIFU treatments of prostate cancer based on acoustic energy density. Proceedings - IEEE Ultrasonics Symposium. Vol. 1 2006. pp. 732-735
@inproceedings{f31de495f17642ee860215f11dc6db31,
title = "Prediction of success for HIFU treatments of prostate cancer based on acoustic energy density",
abstract = "A novel method [1] to predict the probability of success of prostate cancer treatments with HIFU immediately after treatment was developed. It is based on an acoustic energy density measure computed by dividing the energy delivered during a HIFU treatment by the prostate gland volume. This method has been implemented in the Sonablate{\circledR}500 (SB-500) HIFU prostate cancer device (Focus Surgery, Inc., Indianapolis, USA). Its utility was verified by correlating the energy density index to the 180 day post-treatment biopsy results for each subject enrolled in a Phase I clinical trial (N=19) for the primary treatment of organ confined prostate cancer with the SB-500. For each HIFU treatment and at each treatment site the total acoustic power (TAP) and the HIFU {"}ON{"} time were recorded. This information, along with the dimensions of the prostate prior to HIFU treatment and an estimated tissue attenuation coefficient were used to compute the energy density measure. Two values for the attenuation coefficient at 4 MHz were used to estimate the energy absorbed by the prostate: infinite attenuation (α=∞) and finite attenuation (α=0.32 Np/cm). The energy density results for subjects with a negative biopsy were found to be significantly higher than the energy density results for subjects with a positive biopsy when using either infinite or finite attenuation estimates (p<0.02 for both). Receiver operator characteristics (ROC) were computed using the post-treatment biopsy as a gold standard. The area under the ROC curve was found to be 0.77 and 0.80 for infinite and finite attenuation value. This developed energy density measure will not replace current HIFU prostate cancer treatment success indicators (i.e. biopsy), but its ability to be computed immediately post-HIFU treatment and its high correlation with clinical success indicators makes it a useful measure of treatment success.",
keywords = "HIFU, Prostate cancer, Ultrasound",
author = "Fedewa, {Russell J.} and Carlson, {Roy F.} and Ralf Seip and Sanghvi, {Narendra T.} and Michael Koch and Thomas Gardner",
year = "2006",
doi = "10.1109/ULTSYM.2006.196",
language = "English",
isbn = "1424402018",
volume = "1",
pages = "732--735",
booktitle = "Proceedings - IEEE Ultrasonics Symposium",

}

TY - GEN

T1 - Prediction of success for HIFU treatments of prostate cancer based on acoustic energy density

AU - Fedewa, Russell J.

AU - Carlson, Roy F.

AU - Seip, Ralf

AU - Sanghvi, Narendra T.

AU - Koch, Michael

AU - Gardner, Thomas

PY - 2006

Y1 - 2006

N2 - A novel method [1] to predict the probability of success of prostate cancer treatments with HIFU immediately after treatment was developed. It is based on an acoustic energy density measure computed by dividing the energy delivered during a HIFU treatment by the prostate gland volume. This method has been implemented in the Sonablate®500 (SB-500) HIFU prostate cancer device (Focus Surgery, Inc., Indianapolis, USA). Its utility was verified by correlating the energy density index to the 180 day post-treatment biopsy results for each subject enrolled in a Phase I clinical trial (N=19) for the primary treatment of organ confined prostate cancer with the SB-500. For each HIFU treatment and at each treatment site the total acoustic power (TAP) and the HIFU "ON" time were recorded. This information, along with the dimensions of the prostate prior to HIFU treatment and an estimated tissue attenuation coefficient were used to compute the energy density measure. Two values for the attenuation coefficient at 4 MHz were used to estimate the energy absorbed by the prostate: infinite attenuation (α=∞) and finite attenuation (α=0.32 Np/cm). The energy density results for subjects with a negative biopsy were found to be significantly higher than the energy density results for subjects with a positive biopsy when using either infinite or finite attenuation estimates (p<0.02 for both). Receiver operator characteristics (ROC) were computed using the post-treatment biopsy as a gold standard. The area under the ROC curve was found to be 0.77 and 0.80 for infinite and finite attenuation value. This developed energy density measure will not replace current HIFU prostate cancer treatment success indicators (i.e. biopsy), but its ability to be computed immediately post-HIFU treatment and its high correlation with clinical success indicators makes it a useful measure of treatment success.

AB - A novel method [1] to predict the probability of success of prostate cancer treatments with HIFU immediately after treatment was developed. It is based on an acoustic energy density measure computed by dividing the energy delivered during a HIFU treatment by the prostate gland volume. This method has been implemented in the Sonablate®500 (SB-500) HIFU prostate cancer device (Focus Surgery, Inc., Indianapolis, USA). Its utility was verified by correlating the energy density index to the 180 day post-treatment biopsy results for each subject enrolled in a Phase I clinical trial (N=19) for the primary treatment of organ confined prostate cancer with the SB-500. For each HIFU treatment and at each treatment site the total acoustic power (TAP) and the HIFU "ON" time were recorded. This information, along with the dimensions of the prostate prior to HIFU treatment and an estimated tissue attenuation coefficient were used to compute the energy density measure. Two values for the attenuation coefficient at 4 MHz were used to estimate the energy absorbed by the prostate: infinite attenuation (α=∞) and finite attenuation (α=0.32 Np/cm). The energy density results for subjects with a negative biopsy were found to be significantly higher than the energy density results for subjects with a positive biopsy when using either infinite or finite attenuation estimates (p<0.02 for both). Receiver operator characteristics (ROC) were computed using the post-treatment biopsy as a gold standard. The area under the ROC curve was found to be 0.77 and 0.80 for infinite and finite attenuation value. This developed energy density measure will not replace current HIFU prostate cancer treatment success indicators (i.e. biopsy), but its ability to be computed immediately post-HIFU treatment and its high correlation with clinical success indicators makes it a useful measure of treatment success.

KW - HIFU

KW - Prostate cancer

KW - Ultrasound

UR - http://www.scopus.com/inward/record.url?scp=78649384178&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78649384178&partnerID=8YFLogxK

U2 - 10.1109/ULTSYM.2006.196

DO - 10.1109/ULTSYM.2006.196

M3 - Conference contribution

SN - 1424402018

SN - 9781424402014

VL - 1

SP - 732

EP - 735

BT - Proceedings - IEEE Ultrasonics Symposium

ER -